Hostname: page-component-7b7567c8c-wxvwp Total loading time: 0 Render date: 2026-11-17T18:20:47.606Z Has data issue: false hasContentIssue false

Differential effects of typical and atypical antipsychotics on cognitive function in schizophrenia

Published online by Cambridge University Press:  31 July 2026

D. Njah*
Affiliation:
Psychiatry c, Razi psychiatric hospital, Manouba, Tunisia
M. Lagha
Affiliation:
Psychiatry c, Razi psychiatric hospital, Manouba, Tunisia
K. Maagli
Affiliation:
Psychiatry c, Razi psychiatric hospital, Manouba, Tunisia
A. Zyed
Affiliation:
Psychiatry c, Razi psychiatric hospital, Manouba, Tunisia
W. Homri
Affiliation:
Psychiatry c, Razi psychiatric hospital, Manouba, Tunisia
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.
Introduction

Antipsychotics are a mainstay of schizophrenia treatment, effectively controlling psychotic symptoms. However, their impact on cognitive function is attracting growing interest, as cognitive impairment is a major factor in functional disability, affecting memory, attention, and executive functions and consequently impairing quality of life. Understanding the effect of different types of antipsychotics on cognition is essential for adapting therapeutic strategies and optimizing patients’ daily functioning.

Objectives

Our objective was to assess the effect of typical and atypical antipsychotics on cognitive function in patients with schizophrenia and schizoaffective disorder (SAD).

Methods

This was a cross-sectional study including patients with schizophrenia and SAD, aged between 18 and 65 years, that took place over a 2-month period, from February 1, 2025 to April 15, 2025 who were followed up at RAZI psychiatric Hospital in Tunisia. Cognitive function was assessed using the Arabic version of the Montreal Cognitive Assessment (MoCA) scale. Details of patients’ antipsychotic prescriptions were obtained through review of their medical files.

Results

We included 56 patients with schizophrenia and 14 patients with SAD with a mean age of 42 years (SD, 11). Sixty seven percent of our population were male(n=47) and almost 76% (n=53) were single. Among the patients, 27% (n = 19) were receiving atypical antipsychotics (AAP), 52% (n = 36) were on classical antipsychotics (CAP), and 21% (n = 15) were prescribed a combination of both. The median MoCA score was 20(interquartile range, 16-25; range 5-30). Cognitive dysfunction was found in 74,3% of our population(n=52). Patients receiving AAP had significantly higher MoCA scores (p = 0.005), whereas those on CAP showed significantly lower MoCA scores (p = 0.001).

Conclusions

Our findings suggest that the use of first-generation antipsychotics is associated with cognitive impairment, whereas atypical antipsychotics exert a protective effect. These results highlight the importance of carefully selecting antipsychotic treatment to optimize cognitive outcomes in patients with schizophrenia and schizoaffective disorder.

Disclosure of Interest

None Declared

Information

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2026. Published by Cambridge University Press on behalf of European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.